Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Lee

Obstetrics & Gynecology Milton, FL Medical Doctor

NPI 1245276088 CMS profile 328330

5942 Berryhill Rd, Milton, FL 32570

Open in the dashboard

General payments

$11,224

666 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Lee of Milton, FL is reported in the CMS Open Payments database as having received $11,224 across 666 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $641 30
2024 General $1,236 56
2023 General $2,574 122
2022 General $2,150 123
2021 General $1,912 125
2020 General $1,122 75
2019 General $1,590 135

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Lee
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to John Lee were reported at $641. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year John Lee Obstetrics & Gynecology median Middle half National median
2019 $1,590 $172 $62–$391 $163
2020 $1,122 $94 $36–$222 $114
2021 $1,912 $136 $42–$369 $132
2022 $2,150 $160 $50–$433 $149
2023 $2,574 $169 $56–$423 $160
2024 $1,236 $152 $50–$371 $164
2025 $641 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $996 77 payments
  2. AstraZeneca Pharmaceuticals LP $990 39 payments
  3. Novo Nordisk Inc $759 55 payments
  4. Almatica Pharma LLC $754 42 payments
  5. Axsome Therapeutics, Inc. $611 24 payments
  6. Astellas Pharma US Inc $388 9 payments
  7. GlaxoSmithKline, LLC. $381 27 payments
  8. Amgen Inc. $344 21 payments
  9. Kowa Pharmaceuticals America, Inc. $332 23 payments
  10. Lilly USA, LLC $331 23 payments
  11. Other $5,337 326 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,892 657 payments
  2. Education $332 9 payments
Products named General payments · program years 2019–2025
  1. LOREEV XR $754 42 payments
  2. FARXIGA $748 24 payments
  3. Ozempic $482 37 payments
  4. TRELEGY ELLIPTA $381 27 payments
  5. Sunosi $363 15 payments
  6. AIMOVIG $356 21 payments
  7. RYBELSUS $335 21 payments
  8. Livalo $332 23 payments
  9. VRAYLAR $294 20 payments
  10. XYOSTED $268 16 payments
  11. Other $10,082 620 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 136 drugs

Part D claims

5,856

Median for Obstetrics & Gynecology: 65

Drug cost

$663,909

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

26.5%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 151 $159,871
Mounjaro Tirzepatide Brand 72 $79,819
Xyosted Testosterone Enanthate Brand 66 $40,861
Linzess Linaclotide Brand 35 $32,358
Farxiga Dapagliflozin Propanediol Brand 29 $31,581
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 24 $24,378
Eliquis Apixaban Brand 28 $19,232
Trulicity Dulaglutide Brand 14 $19,025
Vascepa Icosapent Ethyl Brand 25 $18,500
Duavee Estrogens,conj/Bazedoxifene Brand 64 $16,635

The 10 drugs with the highest cost, of 136 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOREEV XR
  • Almatica Pharma LLC $241
$241 — —
Sunosi
  • Axsome Therapeutics, Inc. $85
$85 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $80
$80 — —
Wegovy
  • Novo Nordisk Inc $60
$60 — —
Veozah
  • Astellas Pharma US Inc $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

666 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record